BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25576886)

  • 21. Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers.
    Będkowska GE; Gacuta E; Zajkowska M; Głażewska EK; Osada J; Szmitkowski M; Chrostek L; Dąbrowska M; Ławicki S
    J Ovarian Res; 2017 Jun; 10(1):39. PubMed ID: 28662671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
    Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer.
    Tas F; Kilic L; Bilgin E; Keskin S; Sen F; Ciftci R; Yildiz I; Yasasever V
    Int J Gynecol Cancer; 2013 Feb; 23(2):276-81. PubMed ID: 23266651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.
    Kurosaki A; Hasegawa K; Kato T; Abe K; Hanaoka T; Miyara A; O'Shannessy DJ; Somers EB; Yasuda M; Sekino T; Fujiwara K
    Int J Cancer; 2016 Apr; 138(8):1994-2002. PubMed ID: 26595060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of advanced ovarian cancer recurrence by plasma metabolic profiling.
    Zhang H; Ge T; Cui X; Hou Y; Ke C; Yang M; Yang K; Wang J; Guo B; Zhang F; Lou G; Li K
    Mol Biosyst; 2015 Feb; 11(2):516-21. PubMed ID: 25424060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer.
    Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
    Adv Exp Med Biol; 2016; 924():3-8. PubMed ID: 27753009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer.
    Ayhan A; Günakan E; Alyazıcı İ; Haberal N; Altundağ Ö; Dursun P
    Arch Gynecol Obstet; 2017 Nov; 296(5):989-995. PubMed ID: 28875365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.
    Chan KK; Chen CA; Nam JH; Ochiai K; Wilailak S; Choon AT; Sabaratnam S; Hebbar S; Sickan J; Schodin BA; Sumpaico WW
    Gynecol Oncol; 2013 Feb; 128(2):239-44. PubMed ID: 23063998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
    Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
    Onsrud M; Shabana A; Austgulen R
    Tumour Biol; 1996; 17(2):90-6. PubMed ID: 8658018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
    Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
    Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
    Odunsi K; Wollman RM; Ambrosone CB; Hutson A; McCann SE; Tammela J; Geisler JP; Miller G; Sellers T; Cliby W; Qian F; Keitz B; Intengan M; Lele S; Alderfer JL
    Int J Cancer; 2005 Feb; 113(5):782-8. PubMed ID: 15499633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of serum CCL18 as a potential biomarker for ovarian cancer.
    Yuan L; Wan J; Huang C; Liang J; Liu M; Yue C; Li L
    Cancer Biomark; 2017 Dec; 21(1):97-104. PubMed ID: 29036787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of ovarian imaging on the clinical interpretation of a multivariate index assay.
    Goodrich ST; Bristow RE; Santoso JT; Miller RW; Smith A; Zhang Z; Ueland FR
    Am J Obstet Gynecol; 2014 Jul; 211(1):65.e1-65.e11. PubMed ID: 24530816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
    Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
    Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
    Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma immune analytes in patients with epithelial ovarian cancer.
    Block MS; Maurer MJ; Goergen K; Kalli KR; Erskine CL; Behrens MD; Oberg AL; Knutson KL
    Cytokine; 2015 May; 73(1):108-13. PubMed ID: 25743245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.